Picture courtesy PTI
New Delhi: Bharat Biotech on Friday received approval from the Drugs Controller General of India (DCGI) to conduct its intranasal COVID-19 booster dose trials in India.
The trials are likely to be conducted at nine locations across the country, on 900 individuals.
The Subject Expert Committee (SEC) had earlier given in-principle approval for phase III booster dose study of Bharat Biotech’s intranasal COVID vaccine.
The Hyderabad-based pharmaceutical firm had proposed an intranasal booster dose for those who have been administered two doses of Covaxin or Covishield.
Prime Minister Narendra Modi had said last month that India will soon have an indigenous nasal COVID vaccine.
India launched a ‘precautionary’ third dose for frontline workers and senior citizens earlier this month.
Also Read: Intranasal COVID-19 Vaccine More Effective Than Traditional Counterparts
Bhubaneswar: After considerable drop in temperature across Odisha following rain in last few days, the… Read More
New Delhi: Vasundhara Oswal, daughter of Indian-origin billionaire Pankaj Oswal, has raised allegations of causing… Read More
New Delhi: After a prod by the Delhi High Court, Indian Railways has started monitoring… Read More
Bhubaneswar: The Economic Offences Wing (EOW) of Odisha arrested a man from Hyderabad for allegedly… Read More
New Delhi: Following an intelligence warning of a potential abduction plot targeting foreign guests at… Read More
Balasore: A young woman was allegedly killed by a youth after she rejected his advances… Read More
This website uses cookies.
